Athersys, Inc. (NASDAQ:ATHX) plunges 40% after stem cell therapy flunks Phase II stroke trial Print E-mail
By David Fowler   
Friday, 17 April 2015 18:40
In-development stem cell treatment Athersys, Inc. (NASDAQ:ATHX) failed in beating placebo in Phase II trial on stroke patients destroying the firm’s value as management looks for a positive spin.
Read more...
 
FDA gives Fast Track Designation for MediciNova, Inc. (NASDAQ:MNOV)’s MN-001, Shares Up 45% Print E-mail
By Josh Gee   
Thursday, 16 April 2015 15:15
Shares of MediciNova, Inc.(NASDAQ:MNOV) skyrocketed 45% to $5.08 as the company has confirmed receiving Fast Track designation from U.S. Food and Drug Administration for MN-001 that treats patients with nonalcoholic steatohepatitis (NASH) with fibrosis.
Read more...
 
Celsion Corporation (NASDAQ:CLSN) confirms Positive Interim Data from Phase 2 DIGNITY Study in Breast Cancer, Shares Up 22% Print E-mail
By Josh Gee   
Wednesday, 15 April 2015 15:11
Celsion Corporation (NASDAQ:CLSN)’s shares soared 22% to $3.24 as the company has come out with positive interim data from the ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in the recurrent chest wall (RCW) breast cancer. 
Read more...
 
Galena Biopharma Inc (NASDAQ:GALE) finishes Over-Enrollment of NeuVax Phase 3 PRESENT Clinical Trial Print E-mail
By William Kent   
Tuesday, 14 April 2015 15:12
Pharmaceutical firm, Galena Biopharma Inc. (NASDAQ:GALE), has confirmed finishing of enrollment in NeuVax  Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial.
Read more...
 
Arca Biopharma Inc (NASDAQ:ABIO) gets FDA Fast Track Designation for Gencaro, Shares Soar 22% Print E-mail
By Marilyn Mullen   
Monday, 13 April 2015 14:15
Biopharmaceutical firm, Arca Biopharma Inc. (NASDAQ:ABIO), has confirmed that the U.S. Food and Drug Administration (FDA) has given a Fast Track development program for investigating Gencaro that prevents a trial fibrillation in a genetically modified heart failure population.
Read more...
 
Alexion Pharmaceuticals, Inc.(NASDAQ:ALXN) Gets EU Approval for therapeutic indication of Soliris Print E-mail
By David Fowler   
Friday, 10 April 2015 13:35
Alexion Pharmaceuticals, Inc.(NASDAQ:ALXN) has confirmed that European Commission has given approval to EU label for therapeutic indication of Soliris in treatment of paroxysmal nocturnal haemoglobinuria for including patients without history of transfusion.
Read more...
 
Second Sight Medical Products Inc. (NASDAQ:EYES) gains 14% after successful implantation of its Orion I Visual Cortical Prosthesis Print E-mail
By William Kent   
Wednesday, 08 April 2015 14:32
Second Sight Medical Products Inc. (NASDAQ:EYES)’s shares soared 14% after the company has confirmed first successful implant of mechanical model of the Orion or Visual Cortical Prosthesis in the study of an animal.
Read more...
 
Advaxis, Inc. (NASDAQ:ADXS) Jumps 4% On Clinical Trial Collaboration Agreement Print E-mail
By Josh Gee   
Monday, 06 April 2015 15:49
Clinical-stage biotechnology company, Advaxis, Inc.(NASDAQ:ADXS), which is developed cancer immunotherapies has stated that it would be entering into clinical trial collaboration agreement with Radiation Therapy Oncology Group (RTOG) Foundation for evaluating efficacy and safety of ADXS-HPV (ADXS11-001), in a pivotal Phase 2/3 anal cancer trial, that would be run by NRG Oncology.
Read more...
 
Dyax Corp.(NASDAQ:DYAX) Surges 55% on potential of new drug Print E-mail
By Josh Gee   
Thursday, 02 April 2015 15:38
Angioedema drug related positive related during early testing stages led to surge of 55% in the shares of Dyax Corp.(NASDAQ:DYAX) on Wednesday as one of the analyst was wondering if the firm had been able to find a cure for the ailment.
Read more...
 
Can Fite Biopharma Ltd (ADR) NYSEMKT CANF) Slumps On Drug Trial Failure Print E-mail
By Josh Gee   
Tuesday, 31 March 2015 14:31
Biotechnology Company Can Fite Biopharma Ltd (ADR) (NYSEMKT CANF) that is involved in a pipeline of proprietary small molecule drugs addressing cancer and inflammatory diseases has confirmed that the Phase II/III psoriasis trial for the firm’s drug candidate CF101 could not get the desired first endpoint.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 7 of 12

Newsletter